

Saverio Candido

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7781950/publications.pdf>

Version: 2024-02-01

83
papers

4,400
citations

117625

34
h-index

110387

64
g-index

83
all docs

83
docs citations

83
times ranked

7448
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut Microbiota and Cancer: From Pathogenesis to Therapy. <i>Cancers</i> , 2019, 11, 38.	3.7	378
2	Cutaneous melanoma: From pathogenesis to therapy (Review). <i>International Journal of Oncology</i> , 2018, 52, 1071-1080.	3.3	281
3	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. <i>Oncotarget</i> , 2012, 3, 1068-1111.	1.8	279
4	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. <i>Oncotarget</i> , 2012, 3, 954-987.	1.8	244
5	Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. <i>Oncotarget</i> , 2014, 5, 4603-4650.	1.8	231
6	Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. <i>Aging</i> , 2017, 9, 1477-1536.	3.1	168
7	Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. <i>Cells</i> , 2020, 9, 1110.	4.1	146
8	Integrated analysis of colorectal cancer microRNA datasets: identification of microRNAs associated with tumor development. <i>Aging</i> , 2018, 10, 1000-1014.	3.1	135
9	Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. <i>Advances in Biological Regulation</i> , 2015, 59, 65-81.	2.3	121
10	The tumor microenvironment in hepatocellular carcinoma (Review). <i>International Journal of Oncology</i> , 2012, 40, 1733-47.	3.3	111
11	Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. <i>Oncotarget</i> , 2012, 3, 882-892.	1.8	107
12	Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. <i>Advances in Biological Regulation</i> , 2015, 57, 75-101.	2.3	100
13	Identification of Novel MicroRNAs and Their Diagnostic and Prognostic Significance in Oral Cancer. <i>Cancers</i> , 2019, 11, 610.	3.7	94
14	Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. <i>Oncotarget</i> , 2014, 5, 1576-1594.	1.8	91
15	Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. <i>Oncotarget</i> , 2017, 8, 14221-14250.	1.8	86
16	Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (Review). <i>International Journal of Oncology</i> , 2012, 40, 639-44.	3.3	81
17	Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 438-448.	4.1	79
18	Pericytes in Microvessels: From "Mural" Function to Brain and Retina Regeneration. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6351.	4.1	79

#	ARTICLE	IF	CITATIONS
19	Functional Roles of Matrix Metalloproteinases and Their Inhibitors in Melanoma. <i>Cells</i> , 2020, 9, 1151.	4.1	78
20	Cutaneous melanoma and the immunotherapy revolution (Review). <i>International Journal of Oncology</i> , 2020, 57, 609-618.	3.3	75
21	Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. <i>Oncotarget</i> , 2016, 7, 72758-72766.	1.8	73
22	The analysis of miRNA expression profiling datasets reveals inverse microRNA patterns in glioblastoma and Alzheimer's disease. <i>Oncology Reports</i> , 2019, 42, 911-922.	2.6	70
23	Prognostic significance of deregulated microRNAs in uveal melanomas. <i>Molecular Medicine Reports</i> , 2019, 19, 2599-2610.	2.4	69
24	MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA. <i>Frontiers in Pharmacology</i> , 2018, 9, 856.	3.5	68
25	MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma. <i>Aging</i> , 2016, 8, 933-944.	3.1	67
26	Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study. <i>Oncology Letters</i> , 2016, 11, 1021-1025.	1.8	53
27	Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer. <i>PLoS ONE</i> , 2016, 11, e0152104.	2.5	50
28	Metformin influences drug sensitivity in pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2018, 68, 13-30.	2.3	45
29	Analysis of the B-RAFV600E mutation in cutaneous melanoma patients with occupational sun exposure. <i>Oncology Reports</i> , 2014, 31, 1079-1082.	2.6	44
30	Advances in Targeting Signal Transduction Pathways. <i>Oncotarget</i> , 2012, 3, 1505-1521.	1.8	41
31	Emerging targeted therapies for melanoma treatment (Review). <i>International Journal of Oncology</i> , 2014, 45, 516-524.	3.3	39
32	Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. <i>Advances in Biological Regulation</i> , 2017, 65, 77-88.	2.3	39
33	Environment and bladder cancer: molecular analysis by interaction networks. <i>Oncotarget</i> , 2017, 8, 65240-65252.	1.8	39
34	microRNAs and thyroid cancer: Biological and clinical significance. <i>International Journal of Molecular Medicine</i> , 2012, 30, 991-999.	4.0	38
35	Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2019, 71, 172-182.	2.3	34
36	Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. <i>Current Pharmaceutical Design</i> , 2016, 22, 2358-2388.	1.9	34

#	ARTICLE	IF	CITATIONS
37	Droplet Digital PCR Analysis of Liquid Biopsy Samples Unveils the Diagnostic Role of hsa-miR-133a-3p and hsa-miR-375-3p in Oral Cancer. <i>Biology</i> , 2020, 9, 379.	2.8	30
38	Cancer therapy and treatments during COVID-19 era. <i>Advances in Biological Regulation</i> , 2020, 77, 100739.	2.3	30
39	Novel Insights into Epigenetic Regulation of IL6 Pathway: In Silico Perspective on Inflammation and Cancer Relationship. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10172.	4.1	29
40	IL-6-174 G>C and MMP-9-1562 C>T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. <i>Cytokine</i> , 2013, 62, 64-69.	3.2	27
41	Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. <i>Advances in Biological Regulation</i> , 2018, 69, 16-34.	2.3	27
42	BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (Review). <i>Molecular Medicine Reports</i> , 2012, 6, 687-694.	2.4	25
43	Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2019, 73, 100633.	2.3	25
44	Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells. <i>Oncology Letters</i> , 2016, 12, 3363-3367.	1.8	24
45	Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells – Power of nutraceuticals. <i>Advances in Biological Regulation</i> , 2018, 67, 190-211.	2.3	23
46	Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored Treatment. <i>Cancers</i> , 2020, 12, 3636.	3.7	23
47	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. <i>Cell Cycle</i> , 2012, 11, 4447-4461.	2.6	22
48	Molecular Targeted Therapy in Melanoma: A Way to Reverse Resistance to Conventional Drugs. <i>Current Drug Delivery</i> , 2012, 9, 17-29.	1.6	22
49	Prediction of PD-L1 Expression in Neuroblastoma via Computational Modeling. <i>Brain Sciences</i> , 2019, 9, 221.	2.3	22
50	Roles of p53, NF- κ B and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. <i>Advances in Biological Regulation</i> , 2018, 69, 43-62.	2.3	21
51	Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. <i>Advances in Biological Regulation</i> , 2020, 78, 100758.	2.3	21
52	GSK-3 β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. <i>Cells</i> , 2021, 10, 816.	4.1	19
53	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. <i>Oncotarget</i> , 2017, 8, 76525-76557.	1.8	17
54	Computational modeling in melanoma for novel drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 609-621.	5.0	15

#	ARTICLE	IF	CITATIONS
55	Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. <i>Tumor Biology</i> , 2016, 37, 9855-9863.	1.8	15
56	Pomegranate: A promising avenue against the most common chronic diseases and their associated risk factors (Review). <i>International Journal of Functional Nutrition</i> , 2021, 2, .	1.3	15
57	Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. <i>Aging</i> , 2020, 12, 10194-10210.	3.1	15
58	Neopterin: A potential marker in chronic peripheral arterial disease. <i>Molecular Medicine Reports</i> , 2013, 7, 1855-1858.	2.4	13
59	Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity. <i>Oncotarget</i> , 2012, 3, 1236-1245.	1.8	13
60	Update of in vitro, in vivo and ex vivo fluoroâ€denite effects on malignant mesothelioma: A systematic review (Review). <i>Biomedical Reports</i> , 2020, 13, 1-1.	2.0	13
61	Prevalence of hepatitis C virus infection among health-care workers: A 10-year survey. <i>Molecular Medicine Reports</i> , 2010, 3, 561-4.	2.4	11
62	The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3Kâ€Akt Pathways. <i>Pharmaceutics</i> , 2022, 14, 590.	4.5	11
63	Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. <i>Advances in Biological Regulation</i> , 2019, 72, 22-40.	2.3	10
64	Nitric Oxide in Hematological Cancers: Partner or Rival?. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 383-401.	5.4	10
65	Abilities of 1 ² -Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. <i>Advances in Biological Regulation</i> , 2020, 75, 100672.	2.3	9
66	A tailored health surveillance program unveils a case of MALT lymphoma in an HCV-positive health-care worker. <i>Oncology Letters</i> , 2013, 5, 651-654.	1.8	8
67	YY1 Silencing Induces 5-Fluorouracil-Resistance and BCL2L15 Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic Relevance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8481.	4.1	8
68	Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression. <i>Oncotarget</i> , 2017, 8, 113013-113033.	1.8	8
69	Direct oral anticoagulant treatment of deep vein thrombosis reduces ILâ€6 expression in peripheral monoâ€nuclear blood cells. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	1.8	8
70	Low levels of inflammation and the absence of subclinical atherosclerosis in rheumatoid arthritis. <i>Molecular Medicine Reports</i> , 2016, 13, 3521-3524.	2.4	7
71	Role of the Transcription Factor Yin Yang 1 and Its Selectively Identified Target Survivin in High-Grade B-Cells Non-Hodgkin Lymphomas: Potential Diagnostic and Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6446.	4.1	7
72	EpiMethEx: a tool for large-scale integrated analysis in methylation hotspots linked to genetic regulation. <i>BMC Bioinformatics</i> , 2019, 19, 385.	2.6	6

#	ARTICLE	IF	CITATIONS
73	Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. <i>Advances in Biological Regulation</i> , 2021, 79, 100780.	2.3	6
74	Co-Occurrence of Interleukin-6 Receptor Asp358Ala Variant and High Plasma Levels of IL-6: An Evidence of IL-6 Trans-Signaling Activation in Deep Vein Thrombosis (DVT) Patients. <i>Biomolecules</i> , 2022, 12, 681.	4.0	6
75	Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. <i>Advances in Biological Regulation</i> , 2021, , 100840.	2.3	4
76	Overactivation of IL6 cisâ€signaling in leukocytes is an inflammatory hallmark of deep vein thrombosis. <i>Molecular Medicine Reports</i> , 2022, 25, .	2.4	4
77	Interaction between matrix metalloproteinase-9 (MMP-9) and neutrophil gelatinase-associated lipocalin (NGAL): A recent evolutionary event in primates. <i>Developmental and Comparative Immunology</i> , 2021, 116, 103933.	2.3	3
78	Direct oral anticoagulant treatment of deep vein thrombosis reduces IL-6 expression in peripheral mono-nuclear blood cells. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 237.	1.8	1
79	Abstract 4074: Transcription factors involved in the genesis and progression of cancer differently modulated by transforming growth factor-beta3 (TGF-Beta3) in prostate cell lines.. , 2013, , .		0
80	Abstract 4304: MMP-9 as a marker of response to treatment with B-Raf inhibitors in cutaneous melanoma. , 2015, , .		0
81	Abstract 5305: DNA methylation and gene expression in melanoma: A large-scale integrated analysis. , 2018, , .		0
82	Abstract 4836: Diagnostic and prognostic significance of microRNA modulation in oral cancer. , 2020, , .		0
83	Abstract 4687: Oncogenic role of the transcription factor YY1 and its target Survivin in non-Hodgkin's lymphoma. , 2020, , .		0